优化2型严重喘炎症患者管理的区域挑战:七个国家的德尔菲共识
Liam G Heaney1, Desiree Larenas-Linnemann2, Riyad Al-Lehebi3
1Wellcome-Wolfson Institute for Experimental Medicine, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, Belfast, United Kingdom.
概括
发展中国家的专家们达成共识,就2型炎症严重喘的管理达成共识. 及时的生物治疗和生物标志物的使用是改善患者结果和实现临床缓解的关键.
科学领域:
- 肺部病理学 肺部病理学
- 免疫学 免疫学 免疫学
- 临床研究 临床研究
背景情况:
- 严重的喘,特别是具有高埃索诺菲尔水平的第二类 (T2) 炎症,给患者带来了重大负担和管理挑战.
- 生物疗法对于治疗严重的T2喘至关重要,但需要就其在代表性不足的地区的最佳使用达成共识.
研究的目的:
- 为了在发展中国家或通常代表性不足的国家实现专家共识,对严重喘与T2炎症的管理.
- 建立生物标志物利用,治疗选择和定义临床缓解的指南.
主要方法:
- 一项德尔菲共识研究,涉及来自七个发展中国家/代表性不足的国家的呼吸系统专家.
- 两轮在线调查,采用70项陈述问卷,随后参加会议,使用75%的共识门.
主要成果:
- 在调查1中的37/60个陈述和在调查2中的20/47个陈述达成共识.
- 95%的人同意使用生物标志物进行生物选择;100%的人同意及时使用生物药物可以改善酸性喘的结果.
- 专家们定义了临床缓解,并同意避免维持口服皮质类固醇 (OCS),转而直接使用生物疗法.
结论:
- 在代表性不足的环境中,专家们就严重喘管理的关键方面达成了共识.
- 以生物标志物为指导的及时生物干预以及对临床缓解的明确定义对于优化患者护理至关重要.
- 还制定了标准化的转诊标准,促进了更好的患者途径.
相关概念视频
01:30Asthma-IV: Diagnostic and Management
2.5K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.5K
01:26COPD: Management Using Bronchodilators and Corticosteroids
176
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
176
01:30Asthma-IV: Nursing Management
2.9K
The nursing management of asthma is a comprehensive approach that relies heavily on the expertise and dedication of healthcare professionals. It involves thorough assessment, accurate diagnosis, strategic planning, effective implementation, and diligent evaluation. By meticulously following this step-by-step process, healthcare professionals play a crucial role in providing the best possible care and treatment for patients with asthma, enhancing their overall health and well-being.
First, in...
First, in...
2.9K
01:29Chronic Obstructive Pulmonary Disease-V: Management
2.5K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Smoking Cessation
2.5K
01:24Asthma-III: Symptoms and Complications
2.5K
Asthma, a common chronic respiratory condition, is classified considering the frequency and severity of symptoms alongside lung function impairment. Understanding this classification is essential for appropriate treatment and management. Here's a detailed look at the classification of asthma and its clinical features and complications:
Classification of Asthma
Classification of Asthma
2.5K
01:20Asthma: Pathogenesis and Management
346
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
346